Type of security: Stock
Sector: Capital Goods
The data is delayed by 15 minutes.
BIO is in the long-term up 161% in 8 years.
Description: Bio-Rad Laboratories, Inc. manufactures and supplies products and systems used to separate complex chemical and biological materials, as well as to identify, analyze, and purify their components for life science research, healthcare, analytical chemistry, and other markets. The company operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test sy
|Shares Outstanding||EPS||2.61||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-11.92%||Sales Growth - Q/Q||-20.96%||P/E||84.52|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||3.01%||ROE||4.55%||ROI||3.44%|
|Current Ratio||4.08||Quick Ratio||2.93||Long Term Debt/Equity||0.34||Debt Ratio||0.19|
|Gross Margin||54.87%||Operating Margin||7.66%||Net Profit Margin||4.68%||Dividend Payout Ratio|
|Cash From Financing Activities||-330 K||Cash From Investing Activities||-27.99 M||Cash From Operating Activities||29.45 M||Gross Profit||270.11 M|
|Net Profit||17.82 M||Operating Profit||34.35 M||Total Assets||3.33 B||Total Current Assets||1.7 B|
|Total Current Liabilities||416.88 M||Total Debt||435.93 M||Total Liabilities||1.13 B||Total Revenue||472.82 M|
|High 52 week||317.41||Low 52 week||233.97||Last close||296.72||Last change||-0.85%|
|RSI||48.26||Average true range||9.52||Beta||0.73||Volume||71.23 K|
|Simple moving average 20 days||-0.93%||Simple moving average 50 days||-2.38%||Simple moving average 200 days||5.89%|
|Performance Week||-4.62%||Performance Month||1.68%||Performance Quart||9.76%||Performance Half||2.09%|
|Performance Year||10.07%||Performance Year-to-date||-3.49%||Volatility daily||1.85%||Volatility weekly||4.13%|
|Volatility monthly||8.46%||Volatility yearly||29.32%||Relative Volume||236.57%||Average Volume||249.47 K|
|New High||0.51%||New Low|
2020-02-25 16:15:00 | Bio-Rad to Present at Barclays Global Healthcare Conference 2020 on March 10
2020-02-24 17:47:34 | As coronavirus fears hit markets, why are these Bay Area stocks rising?
2020-02-14 10:35:36 | Cyberattack costs East Bay biotech company $20 million
2020-02-14 08:53:01 | Bio-Rad BIO Q4 Earnings & Revenues Fall Short of Estimates
2020-02-14 01:58:53 | Edited Transcript of BIO earnings conference call or presentation 13-Feb-20 10:00pm GMT
2020-02-13 18:45:11 | Bio-Rad Laboratories BIO Misses Q4 Earnings and Revenue Estimates
2020-02-06 12:30:05 | Bio-Rad Laboratories BIO Reports Next Week: Wall Street Expects Earnings Growth
2020-02-04 07:00:00 | Bio-Rad Brings FCS Express Flow Cytometry Analysis Software to ZE5 Cell Analyzer Users
2020-01-09 05:40:52 | Is Bio-Rad Laboratories, Inc.'s NYSE:BIO ROE Of 7.3% Concerning?
2019-12-30 11:47:04 | Bio-Rad Gains on New Product Portfolio Despite Currency Woes
2019-12-25 14:35:10 | Bio-Rad Laboratories, Inc. BIO vs. Top 20 Hedge Fund Stocks in 2019
2019-12-13 16:52:00 | Bio-Rad Makes Progress Recovering from Recent Ransomware Attack
2019-12-11 05:23:04 | Why Bio-Rad Laboratories, Inc. NYSE:BIO Could Be Worth Watching
2019-11-30 14:28:15 | Hedge Funds Have Never Been This Bullish On Bio-Rad Laboratories, Inc. BIO
2019-11-26 12:11:05 | Bio-Rad's Blood Typing Market Growth Strong on New Products
2019-11-11 07:49:08 | Does Bio-Rad Laboratories NYSE:BIO Have A Healthy Balance Sheet?
2019-11-04 11:38:43 | Edited Transcript of BIO earnings conference call or presentation 31-Oct-19 9:00pm GMT
2019-11-01 12:03:04 | Bio-Rad Bio Q3 Earnings Beat Estimates on All-Line Growth
2019-10-31 16:15:00 | Bio-Rad Reports Third-Quarter 2019 Financial Results
2019-10-29 17:09:37 | This Hedge Fund Can Still Deliver Double Digit Returns: Here Are Its Top Picks
2019-10-24 10:32:02 | Bio-Rad Laboratories BIO Earnings Expected to Grow: Should You Buy?
2019-10-23 11:13:00 | 5 Companies Hit 52-Week Highs
2019-10-16 16:15:00 | Bio-Rad to Report Third-Quarter 2019 Financial Results Thursday, October 31, 2019
2019-10-15 12:05:58 | 5 Stocks to Buy in the Mighty Middle
2019-10-12 15:34:00 | Here’s What Hedge Funds Think About Bio-Rad Laboratories, Inc. BIO
2019-10-08 10:36:02 | LabCorp LH Names Two Leaders for Major Business Wings
2019-10-07 06:36:10 | Bruker To Buy Freiberg Instruments' Magnettech EPR Business
2019-10-02 09:48:01 | Abbott ABT Gets FDA Nod for New Troponin-I Blood Test
2019-09-18 09:07:09 | Goldman Sachs: 4 Conviction Buy Stocks To Snap Up Now
2019-09-12 17:28:48 | After record IPO, East Bay company's CEO targets growth — and sleep
2019-09-12 09:55:33 | On eve of biggest biotech IPO this year, 2 East Bay companies spar over patents
2019-09-11 17:48:00 | Bio-Rad Files New Lawsuit Against 10X Genomics for Patent Infringement
2019-08-31 09:31:01 | Bio-Rad BIO Up 8.8% Since Last Earnings Report: Can It Continue?
2019-08-29 18:13:45 | Biome Sees Revenue Quadruple, Gross Profits Triple In Q2
2019-08-29 15:20:07 | Edited Transcript of BIO earnings conference call or presentation 1-Aug-19 9:00pm GMT
2019-08-23 06:51:10 | Here's Why You Should Retain Bio-Rad BIO Stock for Now
2019-08-19 17:45:47 | How a biotech revolution catapulted this East Bay company to a $100M IPO
2019-08-09 09:30:01 | PRGO vs. BIO: Which Stock Is the Better Value Option?
2019-08-02 09:15:01 | Bio-Rad Bio Q2 Earnings Beat Estimates, Margins Expand
2019-08-01 20:26:34 | Bio-Rad Laboratories Inc BIO BIO-B Q2 2019 Earnings Call Transcript
2019-08-01 18:15:10 | Bio-Rad Laboratories BIO Surpasses Q2 Earnings and Revenue Estimates
2019-08-01 16:15:00 | Bio-Rad Reports Second-Quarter 2019 Financial Results